Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare.

A 36 year old man with chronic hepatitis B and cirrhosis was admitted in our Department for the onset of jaundice, ascites and ALT flare (x 35 u.n.v.) while under lamivudine treatment. Serum HBV-DNA was 1.48 x 10(6) IU/ml and lamivudine (LAM) resistance mutations were present. Tenofovir (TDF) 300 mg/day was added to LAM after its off-label use was authorised. HBV-DNA decreased in a biphasic manner and became undetectable by day 45. A parallel improvement in ALT and bilirubin values was detected. Tenofovir was substituted with adefovir dipivoxil 10 mg/day. Ten months after this switch HBV-DNA remained undetectable. Tenofovir is an effective salvage therapy for critically ill patients with LAM-resistant HBV flares and can be switched to adefovir after HBV-DNA becomes undetectable. Local cost and reimbursement policies are important determinants in antiviral therapy.

[1]  H. Chae,et al.  Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV) , 2008, Hepatology international.

[2]  A. Cross,et al.  [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS , 2007 .

[3]  P. Kipnis,et al.  Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV‐coinfected patients: factors associated with response , 2007, Journal of viral hepatitis.

[4]  D. Cooper,et al.  Improvements in Parameters of End-Stage Liver Disease in Patients with HIV/HBV-related Cirrhosis Treated with Tenofovir , 2007, Antiviral therapy.

[5]  V. Johnson,et al.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 , 2006, Hepatology.

[6]  R. Bruno,et al.  Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection , 2006, AIDS.

[7]  C. Lehmann,et al.  Rapid Improvement of Liver Function in a Patient with HIV and Hepatitis B Coinfection Treated with Lamivudine and Tenofovir , 2006, Infection.

[8]  T. Berg,et al.  Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.

[9]  R. D. de Man,et al.  Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  T. Poynard,et al.  Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant , 2006, Comparative Hepatology.

[11]  W. Gerlich,et al.  Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication , 2006, Scandinavian journal of gastroenterology.

[12]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[13]  H. Janssen,et al.  Viral dynamics during tenofovir therapy in patients infected with lamivudine‐resistant hepatitis B virus mutants , 2005, Journal of viral hepatitis.

[14]  A. Casanova,et al.  Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine‐resistant hepatitis B virus awaiting liver transplantation. Post‐transplant results , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  T. Berg,et al.  Reactivation of viral replication after replacement of tenofovir by adefovir , 2005, Hepatology.

[16]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[17]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[18]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.